vs
Side-by-side financial comparison of LISATA THERAPEUTICS, INC. (LSTA) and TREASURE GLOBAL INC (TGL). Click either name above to swap in a different company.
TREASURE GLOBAL INC is the larger business by last-quarter revenue ($182.5K vs $100.0K, roughly 1.8× LISATA THERAPEUTICS, INC.). On growth, TREASURE GLOBAL INC posted the faster year-over-year revenue change (-12.0% vs -90.0%). TREASURE GLOBAL INC produced more free cash flow last quarter ($-2.4M vs $-16.0M).
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
Treasure Global Inc is a consumer technology company offering integrated digital commerce solutions, customer loyalty rewards programs, and cashless payment services. It primarily operates across Southeast Asian markets, serving individual users and small-to-medium enterprise clients.
LSTA vs TGL — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $100.0K | $182.5K |
| Net Profit | — | $-2.1M |
| Gross Margin | — | 0.7% |
| Operating Margin | — | -953.5% |
| Net Margin | — | -1169.1% |
| Revenue YoY | -90.0% | -12.0% |
| Net Profit YoY | 35.9% | -124.5% |
| EPS (diluted) | — | $-0.38 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $100.0K | — | ||
| Q3 25 | $0 | $182.5K | ||
| Q2 25 | $70.0K | $1.2M | ||
| Q1 25 | $0 | $666.5K | ||
| Q4 24 | — | $301.9K | ||
| Q3 24 | $0 | $207.4K | ||
| Q2 24 | $0 | $293.0K | ||
| Q1 24 | $0 | $1.6M |
| Q4 25 | — | — | ||
| Q3 25 | $-4.2M | $-2.1M | ||
| Q2 25 | $-4.7M | — | ||
| Q1 25 | $-4.7M | $1.3M | ||
| Q4 24 | — | $-232.3K | ||
| Q3 24 | $-4.9M | $-950.7K | ||
| Q2 24 | $-5.0M | — | ||
| Q1 24 | $-5.4M | $-1.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.7% | ||
| Q2 25 | — | 68.2% | ||
| Q1 25 | — | 73.0% | ||
| Q4 24 | — | 74.2% | ||
| Q3 24 | — | 83.0% | ||
| Q2 24 | — | 31.0% | ||
| Q1 24 | — | 13.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | -953.5% | ||
| Q2 25 | -6954.3% | — | ||
| Q1 25 | — | -6.5% | ||
| Q4 24 | — | -229.5% | ||
| Q3 24 | — | -391.4% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -85.9% |
| Q4 25 | — | — | ||
| Q3 25 | — | -1169.1% | ||
| Q2 25 | -6655.7% | — | ||
| Q1 25 | — | 189.0% | ||
| Q4 24 | — | -77.0% | ||
| Q3 24 | — | -458.5% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -107.3% |
| Q4 25 | — | — | ||
| Q3 25 | $-0.49 | $-0.38 | ||
| Q2 25 | $-0.54 | — | ||
| Q1 25 | $-0.55 | $1.09 | ||
| Q4 24 | — | $-11.32 | ||
| Q3 24 | $-0.59 | $-17.62 | ||
| Q2 24 | $-0.61 | — | ||
| Q1 24 | $-0.65 | $-116.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $16.0M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $14.9M | $12.0M |
| Total Assets | $17.7M | $16.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $16.0M | — | ||
| Q3 25 | $19.0M | — | ||
| Q2 25 | $16.8M | — | ||
| Q1 25 | $20.2M | $2.5K | ||
| Q4 24 | — | $504.3K | ||
| Q3 24 | $19.5M | $44.1K | ||
| Q2 24 | $28.3M | $171.6K | ||
| Q1 24 | $21.8M | — |
| Q4 25 | $14.9M | — | ||
| Q3 25 | $17.4M | $12.0M | ||
| Q2 25 | $21.0M | $10.7M | ||
| Q1 25 | $25.4M | $29.1M | ||
| Q4 24 | — | $18.4M | ||
| Q3 24 | $33.7M | $6.3M | ||
| Q2 24 | $38.2M | $3.4M | ||
| Q1 24 | $43.0M | $3.1M |
| Q4 25 | $17.7M | — | ||
| Q3 25 | $21.8M | $16.6M | ||
| Q2 25 | $25.2M | $14.9M | ||
| Q1 25 | $29.0M | $30.4M | ||
| Q4 24 | — | $19.1M | ||
| Q3 24 | $38.2M | $7.1M | ||
| Q2 24 | $42.6M | $4.3M | ||
| Q1 24 | $48.2M | $4.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.9M | $-1.8M |
| Free Cash FlowOCF − Capex | $-16.0M | $-2.4M |
| FCF MarginFCF / Revenue | -15977.0% | -1318.2% |
| Capex IntensityCapex / Revenue | 28.0% | 353.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-15.9M | — | ||
| Q3 25 | $-3.3M | $-1.8M | ||
| Q2 25 | $-4.0M | $-9.5M | ||
| Q1 25 | $-5.4M | $-4.2M | ||
| Q4 24 | — | $-606.2K | ||
| Q3 24 | $-2.5M | $-976.3K | ||
| Q2 24 | $-5.3M | $-4.7M | ||
| Q1 24 | $-7.0M | $-1.1M |
| Q4 25 | $-16.0M | — | ||
| Q3 25 | — | $-2.4M | ||
| Q2 25 | — | $-9.5M | ||
| Q1 25 | $-5.4M | $-4.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-4.7M | ||
| Q1 24 | — | $-1.1M |
| Q4 25 | -15977.0% | — | ||
| Q3 25 | — | -1318.2% | ||
| Q2 25 | — | -822.4% | ||
| Q1 25 | — | -635.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -1614.2% | ||
| Q1 24 | — | -67.1% |
| Q4 25 | 28.0% | — | ||
| Q3 25 | — | 353.3% | ||
| Q2 25 | 0.0% | 1.3% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 5.7% | ||
| Q1 24 | — | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -3.36× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
